PipelineReview.com - All Products

Show Cart

All Products

Results 121 - 140 of 193

Jan 2015 Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates

Dec 2014 Recombinant Coagulation Factors 2015: Maturation of recombinant clotting factor pipeline and emergence of gene therapy and alternative procoagulants

(Discount: 10.00%)

Nov 2014 Competitor Analysis: Cancer Peptides

Nov 2014 Competitor Analysis: Cardiometabolic Peptides

Oct 2014 Competitor Analysis: Ebola Virus Vaccines and Therapeutics

Oct 2014 Competitor Analysis: Anti-Infective Peptides

Oct 2014 Competitor Analysis: Cardiovascular Peptides

Sep 2014 Competitor Analysis: Anti-Inflammatory Peptides

Sep 2014 Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins

Aug 2014 Competitor Analysis: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Jul 2014 Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders

(Discount: 25.00%)

Jul 2014 Competitor Analysis: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors

Jun 2014 Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors

Mar 2014 Competitor Analysis: Cancer Vaccines

Mar 2014 2013 Sales of Recombinant Therapeutic Antibodies & Proteins

Jan 2014 Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis

Jan 2014 Competitor Analysis: Immunocytokines

Nov 2013 Competitor Analysis: Janus Kinase (JAK) and spleen tyrosine kinase (syk) Inhibitors

Oct 2013 Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives)

Oct 2013 The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry

Shopping cart

Cart empty

Latest report

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Featured Products

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs:a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Shopping cart

Cart empty

Latest report

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Featured Products

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs:a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

La Merie Biologics

FREE Weekly News Bulletin

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing